Christopher Heery

Company: Arcellx

Job title: Chief Medical Officer

Seminars:

ARC-sparX : A Modular & Universal Cell Platform 11:45 am

An overview of the ARC-sparX platform and how it may be used to address some of the limitations of standard CAR-T cells therapies Modular approach allows for multiple tumour antigen targeting with a universal cell product Control of effector cell and antigen interaction has potential to control expansion kinetics and therefore toxicity profile Combined, this…Read more

day: Day 2 - Track B - Morning